FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 536 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR England: Smoking responsible for twice as many cancers in most deprived... August 2, 2021 Foodie Fridays: Apple Bok Choy Salad September 17, 2021 Black Women Have Nearly Three Times the Risk of Developing Triple... September 22, 2021 An Oncology Hospital at Home Model of Acute Care Shows Promise May 21, 2021 Load more HOT NEWS Study Finds Accelerated Partial-Breast Radiation Just as Effective as Whole Breast... A Positive Trend in OS Improvement Favours Atezolizumab Compared to Best... Cancer in My Community: Caring for Children With Cancer in Paraguay How and When to Wash Your Reusable Cloth Mask and When...
